Literature DB >> 20171752

Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy.

Tarek Hijal1, Nathalie Fournier-Bidoz, Pablo Castro-Pena, Youlia M Kirova, Sophia Zefkili, Marc A Bollet, Rémi Dendale, François Campana, Alain Fourquet.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate the dosimetry of helical tomotherapy (HT) and three-dimensional conformal radiotherapy (3D-CRT) in breast cancer patients undergoing whole breast radiation with simultaneous integrated boost (SIB) of the tumor bed.
MATERIAL AND METHODS: Thirteen patients with breast cancer treated by lumpectomy and requiring whole breast radiotherapy with tumor bed boost were planned using both HT and 3D-CRT using the field-in-field technique. The whole breast and tumor bed were prescribed 50.68 Gy and 64.4 Gy, respectively, in 28 fractions. Dosimetries for both techniques were compared.
RESULTS: Coverage of the whole breast was adequate with both techniques (V(95%)=96.22% vs. 96.25%, with HT and 3D-CRT, respectively; p=0.64). Adequate tumor bed coverage was also achieved, although it was significantly lower with HT (V(95%)=97.18% vs. 99.72%; p<0.001). Overdose of the breast volume outside the tumor bed was significantly lower with HT (V(54.23 Gy)=12.47% vs. 30.83%; p<0.001). Ipsilateral lung V(20 Gy) (6.34% vs. 10.17%; p<0.001), V(5 Gy) (16.54% vs. 18.53%; p<0.05) and mean dose (4.05 Gy vs. 6.36 Gy; p<0.001) were significantly lower with HT. In patients with left-sided tumors, heart V(30 Gy) (0.03% vs. 1.14%; p<0.05) and mean dose (1.35 Gy vs. 2.22 Gy; p<0.01) were significantly lower with HT, but not V(5 Gy). Contralateral breast V(5 Gy) (0.27% vs. 0.00%; p<0.01) and maximum dose were significantly increased with HT.
CONCLUSIONS: In breast cancer treated with SIB, both HT and 3D-CRT provided adequate target volume coverage and low heart doses. Tumor bed coverage was slightly lower with HT, but HT avoided unnecessary breast overdosage while improving ipsilateral lung dosimetry. (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20171752     DOI: 10.1016/j.radonc.2009.12.043

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  29 in total

1.  AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Authors:  Christoph Thomssen; Anton Scharl; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2011-08-30       Impact factor: 2.860

2.  Helical tomotherapy in patients with breast cancer and complex treatment volumes.

Authors:  Ricardo Cendales; Luis Schiappacasse; Franco Schnitman; Graciela García; Hugo Marsiglia
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

3.  Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial.

Authors:  Pierfrancesco Franco; Michele Zeverino; Fernanda Migliaccio; Domenico Cante; Piera Sciacero; Valeria Casanova Borca; Paolo Torielli; Cecilia Arrichiello; Giuseppe Girelli; Maria Rosa La Porta; Santi Tofani; Gianmauro Numico; Umberto Ricardi
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-30       Impact factor: 4.553

4.  Beam angle manipulation to reduce cardiac dose during breast radiotherapy.

Authors:  S Vivekanandan; J Mhlanga; D Launders; A Przeslak; D A L Morgan
Journal:  Br J Radiol       Date:  2011-07-12       Impact factor: 3.039

Review 5.  Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence.

Authors:  Pierfrancesco Franco; Domenico Cante; Piera Sciacero; Giuseppe Girelli; Maria Rosa La Porta; Umberto Ricardi
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

6.  Breast cancer and funnel chest. Comparing helical tomotherapy and three-dimensional conformal radiotherapy with regard to the shape of pectus excavatum.

Authors:  M Uhl; F Sterzing; G Habl; K Schubert; H Holger; J Debus; K Herfarth
Journal:  Strahlenther Onkol       Date:  2012-01-06       Impact factor: 3.621

7.  Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy.

Authors:  Olivier Lauche; Youlia M Kirova; Pascal Fenoglietto; Emilie Costa; Claire Lemanski; Celine Bourgier; Olivier Riou; David Tiberi; Francois Campana; Alain Fourquet; David Azria
Journal:  World J Radiol       Date:  2016-08-28

8.  Acute Toxicity From Breast Cancer Radiation Using Helical Tomotherapy With a Simultaneous Integrated Boost.

Authors:  Andrzej P Wojcieszynski; Anna K Olson; Yi Rong; Randall J Kimple; Poonam Yadav
Journal:  Technol Cancer Res Treat       Date:  2015-03-16

9.  Dosimetric Comparison of Sequential Versus Simultaneous-integrated Boost in Early-stage Breast Cancer Patients Treated With Breast-conserving Surgery.

Authors:  Cem Onal; Esma Efe; Ozan C Guler; Berna A Yildirim
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

10.  Comparison of plan optimization for single and dual volumetric-modulated arc therapy versus intensity-modulated radiation therapy during post-mastectomy regional irradiation.

Authors:  Li-Rong Zhao; Yi-Bing Zhou; Jian-Guo Sun
Journal:  Oncol Lett       Date:  2016-03-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.